Soleno TherapeuticsSLNO
SLNO
About: Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Employees: 92
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
212% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 25
100% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 24
16% more funds holding
Funds holding: 142 [Q3] → 165 (+23) [Q4]
2% less call options, than puts
Call options by funds: $120M | Put options by funds: $123M
4% less capital invested
Capital invested by funds: $2.38B [Q3] → $2.29B (-$85M) [Q4]
2.86% less ownership
Funds ownership: 121.22% [Q3] → 118.37% (-2.86%) [Q4]
11% less funds holding in top 10
Funds holding in top 10: 9 [Q3] → 8 (-1) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$81
18%
upside
Avg. target
$103
50%
upside
High target
$123
78%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju 29% 1-year accuracy 96 / 335 met price target | 45%upside $100 | Buy Reiterated | 15 Apr 2025 |
Stifel James Condulis 33% 1-year accuracy 1 / 3 met price target | 57%upside $108 | Buy Maintained | 28 Mar 2025 |
Guggenheim Debjit Chattopadhyay 17% 1-year accuracy 4 / 23 met price target | 18%upside $81 | Buy Maintained | 28 Mar 2025 |
Laidlaw & Co. Yale Jen 17% 1-year accuracy 1 / 6 met price target | 52%upside $105 | Buy Maintained | 27 Mar 2025 |
Baird Brian Skorney 27% 1-year accuracy 6 / 22 met price target | 48%upside $102 | Outperform Maintained | 27 Mar 2025 |
Financial journalist opinion
Based on 5 articles about SLNO published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Soleno Therapeutics Announces VYKAT(TM) XR Launch
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company's treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025.
Positive
Zacks Investment Research
3 weeks ago
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
Positive
Investors Business Daily
3 weeks ago
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher
Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed. The post Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher appeared first on Investor's Business Daily.
Positive
Benzinga
3 weeks ago
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
The U.S. Food and Drug Administration (FDA) on Wednesday approved Soleno Therapeutics, Inc.'s SLNO Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
Neutral
GlobeNewsWire
3 weeks ago
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th , at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
Neutral
GlobeNewsWire
2 months ago
Soleno Therapeutics to Participate in Upcoming February Investor Conferences
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February:
Neutral
GlobeNewsWire
4 months ago
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million.
Neutral
GlobeNewsWire
4 months ago
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.
Neutral
GlobeNewsWire
4 months ago
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.
Neutral
GlobeNewsWire
5 months ago
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK.
Charts implemented using Lightweight Charts™